MovDisordV3, PascalFrancis, Curation, bibRecord, 001069

Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects

Identifieur interne : 001069 ( PascalFrancis/Curation ); précédent : 001068; suivant : 001070

Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects

Auteurs : Katie Kompoliti [États-Unis] ; Christopher G. Goetz [États-Unis] ; Mary Morrissey [États-Unis] ; Sue Leurgans [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0171953

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Gilles de la Tourette syndrome, Tic, Dyskinésie, Homme, Dopamine, Neuroleptique, Toxicité.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Dopamine, Dyskinesia, Gilles de la Tourette syndrome, Human, Nervous system diseases, Neuroleptic, Tic, Toxicity.

Abstract

The objective of this study was to assess awareness and concern of neuroleptic (NL)-induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in-person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL-naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL-naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects`
A11	`01`	`1`		`@1 KOMPOLITI (Katie)`
A11	`02`	`1`		`@1 GOETZ (Christopher G.)`
A11	`03`	`1`		`@1 MORRISSEY (Mary)`
A11	`04`	`1`		`@1 LEURGANS (Sue)`
A14	`01`			`@1 Department of Neurological Sciences, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 248-252`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000153398400180`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 7 ref.`
A47	`01`	`1`		`@0 06-0171953`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The objective of this study was to assess awareness and concern of neuroleptic (NL)-induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in-person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL-naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL-naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17F`
C02	`03`	`X`		`@0 002B16B`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Gilles de la Tourette syndrome @5 02`
C03	`02`	`X`	`ENG`	`@0 Gilles de la Tourette syndrome @5 02`
C03	`02`	`X`	`SPA`	`@0 Gilles de la Tourette síndrome @5 02`
C03	`03`	`X`	`FRE`	`@0 Tic @5 03`
C03	`03`	`X`	`ENG`	`@0 Tic @5 03`
C03	`03`	`X`	`SPA`	`@0 Tic @5 03`
C03	`04`	`X`	`FRE`	`@0 Dyskinésie @5 04`
C03	`04`	`X`	`ENG`	`@0 Dyskinesia @5 04`
C03	`04`	`X`	`SPA`	`@0 Disquinesia @5 04`
C03	`05`	`X`	`FRE`	`@0 Homme @5 09`
C03	`05`	`X`	`ENG`	`@0 Human @5 09`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 09`
C03	`06`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 10`
C03	`06`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 10`
C03	`06`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 10`
C03	`07`	`X`	`FRE`	`@0 Neuroleptique @5 11`
C03	`07`	`X`	`ENG`	`@0 Neuroleptic @5 11`
C03	`07`	`X`	`SPA`	`@0 Neuroléptico @5 11`
C03	`08`	`X`	`FRE`	`@0 Toxicité @5 12`
C03	`08`	`X`	`ENG`	`@0 Toxicity @5 12`
C03	`08`	`X`	`SPA`	`@0 Toxicidad @5 12`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Mouvement involontaire @5 40`
C07	`04`	`X`	`ENG`	`@0 Involuntary movement @5 40`
C07	`04`	`X`	`SPA`	`@0 Movimiento involuntario @5 40`
C07	`05`	`X`	`FRE`	`@0 Trouble neurologique @5 41`
C07	`05`	`X`	`ENG`	`@0 Neurological disorder @5 41`
C07	`05`	`X`	`SPA`	`@0 Trastorno neurológico @5 41`
C07	`06`	`X`	`FRE`	`@0 Catécholamine @5 42`
C07	`06`	`X`	`ENG`	`@0 Catecholamine @5 42`
C07	`06`	`X`	`SPA`	`@0 Catecolamina @5 42`
C07	`07`	`X`	`FRE`	`@0 Neurotransmetteur @5 43`
C07	`07`	`X`	`ENG`	`@0 Neurotransmitter @5 43`
C07	`07`	`X`	`SPA`	`@0 Neurotransmisor @5 43`
C07	`08`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 44`
C07	`08`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 44`
C07	`08`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 44`
N21				`@1 107`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C52

Links to Exploration step

Pascal:06-0171953

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects</title>
<author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0171953</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0171953 INIST</idno>
<idno type="RBID">Pascal:06-0171953</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C52</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001069</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects</title>
<author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term>
<term>Dyskinesia</term>
<term>Gilles de la Tourette syndrome</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Neuroleptic</term>
<term>Tic</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Gilles de la Tourette syndrome</term>
<term>Tic</term>
<term>Dyskinésie</term>
<term>Homme</term>
<term>Dopamine</term>
<term>Neuroleptique</term>
<term>Toxicité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to assess awareness and concern of neuroleptic (NL)-induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in-person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL-naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL-naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KOMPOLITI (Katie)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MORRISSEY (Mary)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LEURGANS (Sue)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>248-252</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000153398400180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>7 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0171953</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The objective of this study was to assess awareness and concern of neuroleptic (NL)-induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in-person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL-naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL-naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B16B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Gilles de la Tourette syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Gilles de la Tourette syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Gilles de la Tourette síndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tic</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Tic</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tic</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>44</s5>
</fC07>
<fN21><s1>107</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001069 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001069 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0171953
   |texte=   Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects

Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri